PetVivo Holdings, Inc. Announces Scheduled Presentations by PetVivo Veterinarians at the American Association of Equine Practitioners Convention in San Diego, California
Tom Yarbrough, DVM, ACVS, the Director of Product Research for PetVivo Holdings Inc., is providing a presentation entitled “Modern Wild West: Navigating the new classes of joint therapeutics”.
MINNEAPOLIS, MN, US, Nov. 02, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today that two members of PetVivo’s Scientific/Veterinarian Team, Tom Yarbrough, DVM, ACVS and Joseph Manning, DVM, MBA, will present at the American Association of Equine Practitioners (“AAEP”) annual convention to be held November 30th to December 2nd, 2023 at the San Diego Convention Center in San Diego, California.
Tom Yarbrough, DVM, ACVS, the Director of Product Research for PetVivo Holdings Inc., is providing a presentation entitled “Modern Wild West: Navigating the new classes of joint therapeutics”. In addition, Joseph Manning, DVM, MBA, Senior Technical Veterinarian for PetVivo Holdings, inc., will be discussing the use of Spryng™ with OsteoCushion™ Technology in a presentation entitled “Advancements in Intra-Articular Therapies: Experiences with a novel collagen-elastin hydrogel microparticles (CEHM) biomaterial used intra-articularly for joint conditions in equines”. If you would like to attend the presentations by Dr. Yarbrough and Dr. Manning the details are provided below.
PetVivo’s innovative product, SPRYNG™ with OsteoCushion™ Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles; Spryng microparticles perform in the joint as wet, slippery micro-cushions used in the management of lameness and other joint related afflictions, such as osteoarthritis.
“We are incredibly honored to have two members of our Scientific/Veterinarian Team presenting at one of the premier conventions for equine veterinarians in the world,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We welcome the opportunity to support the AAEP, as well as the chance to share the knowledge of two of our incredibly talented veterinarians, Tom Yarbrough and Joe Manning.”
Dr. Thomas Yarbrough Presentation Schedule:
Presentation Title: Modern Wild West: Navigating the new classes of joint therapeutics
Presentation Date: Friday, December 1: 11:00 a.m. - 11:30 a.m.
Location for Presentation 1: San Diego Convention Center: Theater 2
Dr. Joseph Manning Presentation Schedule:
Presentation Title: Advancements in Intra-Articular Therapies: Experiences with a novel collagen-elastin hydrogel microparticles (CEHM) biomaterial used intra-articularly for joint conditions in equines
Presentation Date: Thursday, November 30: 11:00 a.m. - 11:30 a.m.
Location for Presentation 2: San Diego Convention Center: Theater 2
For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact [email protected] or visit https://petvivo.com/ and https://sprynghealth.com/.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact [email protected] or visit https://petvivo.com/ or http://sprynghealth.com.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: [email protected]
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2023 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
